ICU
SeaStar Medical Holding CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
9.12
P/S
10.35
EV/EBITDA
-0.11
DCF Value
$4.00
FCF Yield
-106.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.7%
Operating Margin
-986.6%
Net Margin
-984.6%
ROE
-188.5%
ROA
-85.8%
ROIC
-111.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $420.0K | $-2.9M | $-0.80 |
| FY 2025 | $1.2M | $-12.2M | $-5.86 |
| Q3 2025 | $183.0K | $-3.5M | $-1.30 |
| Q2 2025 | $338.0K | $-2.0M | $-1.10 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.19
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.